



AMENDMENTS TO THE SPECIFICATION

Amend the paragraphs commencing on page 3, line 1, through page 5, line 25 as follows
(changes are highlighted):

In a first aspect, this invention is compounds of formula I or formula I'



where:



m is an integer selected from 0, 1, and 2;

n and o are integers independently selected from 0 and 1;

A is selected from the group consisting of N and CH;

B is selected from the group consisting of -CH₂-CH₂-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-NH-,
-CH₂-O-CH₂-, -CH₂-S-CH₂-, -C(=O)-NH-, -C(=O)-CH₂-, -CH₂-C(=O)-NH-, -C(=O)-CH₂-C(=O)-,
-C(=O)-NH-CH₂-, -C(=O)-, -S(=O)-, -S(=O)₂-, -S(=O)-NH-, -S(=O)₂-NH-, -S(=O)-CH₂-,
-S(=O)₂-CH₂-, -S(=O)-CH₂-NH-, -S(=O)₂-CH₂-NH-, -S(=O)₂-NH-CH₂-, -CH₂-S(=O)₂-NH-,
-C(=O)-NH-S(=O)₂-, -S(=O)₂-NH-C(=O)-, -C(=O)-CH₂-S(=O)₂-, and -S(=O)₂-CH₂-C(=O)-;

J is absent or selected from the group consisting of $-O-$, $-S-$, $-CHR^{15}-O-$, $-CH_2-CHR^{15}-O-$, $-NH-$, $-NH-CHR^{15}-$, ~~$-NH-(C_2-C_6\text{alkyl})-$~~ , $-NH-CHR^{15}-C(=O)-$, $-C(=O)-$, $-CH_2-$, $-CHR^{15}-CH_2-NH-$, $-C(=O)-CHR^{15}-$, $-NH-C(=O)-CH(C_1-C_6\text{alkyl})-$, $-NH-C(=O)-CH(C_3-C_{12}\text{cycloalkyl})-$, $-CH_2-CH_2-$, $-CH_2NH-$, $-CH_2-NH-C(=O)-$, $-CH_2-NH-C(=O)-C_1-C_6\text{alkyl}-$, $-CH_2-NH-C(=O)-CH(C_3-C_{12}\text{cycloalkyl})-$ and $-C(=O)-CHR^{15}-NH-$;

L is selected from the group consisting of $-O-$, $-CH_2-O-$, $-O-CH_2-$, $-CH_2-CH_2-O-$, $-O-CH_2-CH_2-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-C(=O)-NH-$, $-O-C(=O)-NH-$, $-CH_2-C(=O)-NH-$, $-C(=O)-CH_2-NH-$, $-C(=O)-NH-CH_2-$, $-NH-C(=O)-$, $NH-C(=O)-O-$, $-NH-CH_2-C(=O)-$, $-NH-C(=O)-CH_2-$, $-CH_2-NH-C(=O)-$, $-NH-C(=O)-NH-$, $-NH-S(=O)_2-NH-$, $-NH-S(=O)_2-$, $-NH-S(=O)_2-CH_2-$, $-CH_2-NH-S(=O)_2-$, $-S(=O)_2-NH-$, $-S(=O)_2-NH-CH_2-$, $-CH_2-S(=O)_2-NH-$, $-C(=O)-NH-S(=O)_2-$, $-S(=O)_2-NH-C(=O)-$, $-CH_2-NH-$, $-CH_2-CH_2-NH-$, $-NH-CH_2-$, $-NH-CH_2-CH_2-$, $-CH_2-NH-CH_2-$, $-C\equiv C-$, $-CH_2-C\equiv C-$, $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH=CH-$, $CH=CH-CH_2-$, and $-CH=CH-$;


M is selected from the group consisting of R^9 and an optionally substituted group selected from phenyl, naphthyl, C_3-C_7 -cycloalkyl, and heterocyclyl, the heterocyclyl group being aliphatic, partially unsaturated, or aromatic, and containing 1 or 2 rings each containing 5-7 ring atoms of which 0-3 are hetero atoms selected from N, O and S, provided that at least one ring contains a heteroatom and where any ring carbon or sulfur may optionally be oxidized, the optional substituents being up to three groups selected from R^1 , R^2 and R^9 ;

Q is selected from the group consisting of $-C(=O)OR^{16}$, $-C(=O)-NH-C(=O)-CF_3$, $-C(=O)-NH-S(=O)_2-R^2$, $-C(=O)-NR^1-OH$, 5-oxo-4,5-dihydro[1,2,4]oxadiazol-3-yl, and tetrazolyl;

X is A when n is 1, and is CH, N, O or S when n is 0;

R^1 is selected from the group consisting of hydrogen, $(C_1-C_6)\text{alkyl}$, halo- $(C_1-C_6)\text{alkyl}$, and $(C_3-C_6)\text{cycloalkyl}$;

R^2 , R^3 and R^5 are individually selected from the group consisting of hydrogen, cyano, nitro, phenyl, phenoxy, benzyl, $C_1-C_6\text{alkyl}$, halo, halo- $C_1-C_6\text{alkyl}$, $C_3-C_6\text{cycloalkyl}$, $C_1-C_6\text{alkoxy}$, hydroxy, $C_1-C_2\text{alkoxy-methoxy}$, hydroxy- $C_1-C_6\text{alkyl}$, formyl, $C_1-C_6\text{alkylcarbonyl}$, amino, $C_1-C_6\text{alkylamino}$, aminocarbonyl, $C_1-C_6\text{alkylaminocarbonyl}$, formylamino, and $C_1-C_6\text{alkylcarbonylamino}$, where any alkyl or phenyl may optionally be substituted with halo or Q;



R^4 is selected from the group consisting of R^2 and

where Ar is a homo- or hetero-aryl group having 1 or 2 rings, each ring containing 5, 6 or 7 ring atoms of which 1-3 may be heteroatoms selected from N, O and S;

R^6 is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, halo, halo- C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, hydroxy, hydroxy- C_1 - C_6 alkyl, $HC(=O)$ - C_1 - C_6 alkyl, carboxy, carboxy- C_1 - C_6 alkyl, carbonylamino- C_1 - C_6 alkyl, aminocarbonyl, (C_1 - C_6 alkyl)aminocarbonyl, di(C_1 - C_6 alkyl)aminocarbonyl, and aminocarbonyl- C_1 - C_6 alkyl;

R^7 is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, halo, halo- C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, hydroxy, hydroxy- C_1 - C_6 alkyl, $HC(=O)$ - C_1 - C_6 alkyl, carboxy, carboxy- C_1 - C_6 alkyl, carbonylamino- C_1 - C_6 alkyl, aminocarbonyl, (C_1 - C_6 alkyl)aminocarbonyl, di(C_1 - C_6 alkyl)aminocarbonyl, and aminocarbonyl- C_1 - C_6 alkyl;

$R^{7'}$ is hydrogen; or

R^7 and $R^{7'}$ together with the carbon to which they are bonded form $-C(=O)-$;

R^8 is selected from the group consisting of hydrogen, hydroxy, C_1 - C_6 alkoxy, C_1 - C_6 alkyl, halo, halo- C_1 - C_6 alkyl, and C_3 - C_6 cycloalkyl;

R^9 is selected from the group consisting of $-NR^{10}R^{11}$, $-C(=NR^{12})-NHR^{13}$, $-N=CR^{14}-NR^{10}R^{11}$, $-NR^{13}-CR^{14}=NR^{12}$, and $-NR^{13}-C(=NR^{12})-NHR^{13}$, $=NH$ and $-CH=NH$;

R^{10} , R^{11} , R^{12} , R^{13} and R^{14} are independently selected from the group consisting of hydrogen, hydroxy, hydroxy- C_1 - C_6 alkyl, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, and C_3 - C_7 cycloalkyl; or any member of the group R^{10} , R^{11} , R^{12} , R^{13} , and R^{14} together with the nitrogen to which it is attached forms a 5, 6 or 7 member heterocycle with any other member of the group, the heterocycle optionally containing one additional heteroatom selected from N, O and S;


R^{15} is selected from the group consisting of hydrogen, C_1 - C_{12} alkyl, C_3 - C_7 cycloalkyl, aminocarbonyl, C_1 - C_6 alkylaminocarbonyl, and di(C_1 - C_6 alkyl)aminocarbonyl; and

R^{16} is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, C_3 - C_{13} cycloalkyl, C_6 - C_{10} aryl, acetylamino- C_1 - C_{12} alkyl, C_1 - C_6 alkylcarbonyloxy- C_1 - C_6 alkyl, and C_6 - C_{10} aryl- C_0 - C_6 alkylcarbonyloxy- C_1 - C_6 alkyl, and the pharmaceutically acceptable salts thereof;

β'

provided that the compound is not N-[2-[1-(aminoiminomethyl)-3-piperidiny]-1-oxoethyl]-4-phenylethynyl-phenylalanine methyl ester or a pharmaceutically acceptable salt thereof.

Replace the data on Page 10, lines 5-11 with the following data (the only change is the



addition of a connecting bond to which was inadvertently omitted in the previously filed preliminary amendment):

